Eduardo Perna (@eduardoperna1) 's Twitter Profile
Eduardo Perna

@eduardoperna1

Ex-Presidente Federación Argentina de Cardiología. Jefe División Insuficiencia Cardiaca e Hipertensión Pulmonar. Instituto de Cardiología de Corrientes 🇦🇷

ID: 1257288452581863430

calendar_today04-05-2020 12:38:38

3,3K Tweet

1,1K Followers

596 Following

Daniel Piskorz (@danielpiskorz) 's Twitter Profile Photo

Consenso Síndromes Coronarios Crónicos 2023 de la Federación Argentina de Cardiología. Disponible con ACCESO LIBRE Y GRATUITO en revistafac.org.ar/ojs/index.php/…

Consenso Síndromes Coronarios Crónicos 2023 de la Federación Argentina de Cardiología. Disponible con ACCESO LIBRE Y GRATUITO en revistafac.org.ar/ojs/index.php/…
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

👁️Left Ventricular Ejection Fraction and the Future of #HF Phenotyping 👉#HF is a complex syndrome categorized by LVEF 👉 LVEF is prognostic for adverse events and predicts response to some medical therapies 👉Simplified LVEF terminology may improve utilization ofHF💊

👁️Left Ventricular Ejection Fraction and the Future of #HF Phenotyping

👉#HF  is a complex syndrome categorized by LVEF

👉 LVEF is prognostic for adverse events and predicts response to some medical therapies

👉Simplified LVEF terminology may improve utilization ofHF💊
Jesús Álvarez-García (@j_alvarezgarcia) 's Twitter Profile Photo

Excited to share "Sacubitril/valsartan: Where mechanism meets evidence-based medicine" in European Society of Cardiology Journals with the emerging star Sonia Rivas ✨ Cardiología RyC 🆕acortar.link/ZTskqZ Our opinion about a very interesting paper from Juhani Knuuti et al (acortar.link/uYuFZC)

Excited to share "Sacubitril/valsartan: Where mechanism meets evidence-based medicine" in <a href="/ESC_Journals/">European Society of Cardiology Journals</a> with the emerging star Sonia Rivas ✨  <a href="/CardiologiaRyC/">Cardiología RyC</a> 
🆕acortar.link/ZTskqZ

Our opinion about a very interesting paper from <a href="/JuhaniKnuuti/">Juhani Knuuti</a> et al (acortar.link/uYuFZC)
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

⚠️Heart failure, sleep apnea and dapagliflozin: #DAPA-HF & #DELIVER 🎯worsening HF or CV☠️ 📈prevalence of sleep apnea was 5.7% and 7.8% in HFrEF and HFmrEF/HFpEF, respectively 👉WHF/CV☠️ 16% with sleep apnea vs 10.6%-years in those without 💊dapagliflozin ⤵️ the risk of the

⚠️Heart failure, sleep apnea and dapagliflozin: #DAPA-HF &amp; #DELIVER

🎯worsening HF or CV☠️
 
📈prevalence of sleep apnea was 5.7% and 7.8% in HFrEF and HFmrEF/HFpEF, respectively

👉WHF/CV☠️ 16% with sleep apnea vs 10.6%-years in those without

💊dapagliflozin ⤵️ the risk of the
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

⚠️Optimization of Evidence-Based Heart Failure Medications After an Acute #HF🏥 #STRONG-HF 👥515, 2 weeks after discharge, medium- to high-dose GDMT💊 was prescribed in more than 90% of patients 👉👥 with ⤵️ blood pressure, ↗️ congestion were less uptitrated 👉👥 prescribed

⚠️Optimization of Evidence-Based Heart Failure Medications After an Acute #HF🏥 #STRONG-HF

👥515, 2 weeks after discharge, medium- to high-dose GDMT💊 was prescribed in more than 90% of patients

👉👥 with ⤵️ blood pressure, ↗️ congestion were less uptitrated

👉👥 prescribed
aldo prado (@aldoprado) 's Twitter Profile Photo

Diplomatura en Imágenes 2024. Facultad de Medicina-Universidad Nacional de Tucumán- modalidad 100% virtual. Comienzo en marzo 2024. información en [email protected]

Diplomatura en Imágenes 2024. Facultad de Medicina-Universidad Nacional de Tucumán- modalidad 100% virtual. Comienzo en marzo 2024. información en diolomaturaenimagenes@gmail.com
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

Dapagliflozin and Mode of ☠️ in #HF With Improved EF #DELIVER Trial 👥 1151 with HFimpEF in DELIVER👇 📌190 (16.5%) ☠️ vs 833 (16.3%) of 5112 with LVEF consistently > 40% 📌 Most ☠️ with HFimpEF were nonCV 📌For CV☠️▶️sudden deaths were most common (36 of 190 events [19%]),

Dapagliflozin and Mode of ☠️ in #HF With Improved EF
#DELIVER Trial
👥 1151 with HFimpEF in DELIVER👇

📌190 (16.5%) ☠️ vs  833 (16.3%) of 5112 with LVEF consistently &gt; 40%

📌 Most ☠️  with HFimpEF were nonCV

📌For CV☠️▶️sudden deaths were most common (36 of 190 events [19%]),
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

⚠️Angiotensin Receptor Neprilysin Inhibition Across Ejection Fraction and Acuity Spectra in #HF via Peder L. Myhre MD, PhD & Carolyn Lam 👉PARADIGM-HF, 👉PARAGON-HF 👉PIONEER-HF 👉PARAGLIDE-HF, 📌 covering all 4 corners of the stage C HF acuity-by-LVEF spectra 📌clear benefit of ARNI over

⚠️Angiotensin Receptor Neprilysin
Inhibition Across Ejection Fraction and Acuity Spectra in #HF via <a href="/pmyhre/">Peder L. Myhre MD, PhD</a> &amp; <a href="/lamcardio/">Carolyn Lam</a> 

👉PARADIGM-HF, 
👉PARAGON-HF
👉PIONEER-HF
👉PARAGLIDE-HF,
📌 covering all 4 corners of the stage C HF acuity-by-LVEF spectra
📌clear benefit of ARNI over
Julia Seller (@juliasellerm) 's Twitter Profile Photo

Top3 heart failure trials in January 2024 🥇AF in AHF: A position statement from the #ACVC and #EHRA of European Society of Cardiology 🥈Integration of implantable device therapy in patients with HF. A clinical consensus statement from the #AHF and #EHRA of European Society of Cardiology 🥉ARNI across EF and

Top3 heart failure trials in January 2024

🥇AF  in AHF: A position statement from the #ACVC and #EHRA of <a href="/escardio/">European Society of Cardiology</a> 

🥈Integration of implantable device therapy in patients with HF. A clinical consensus statement from the #AHF  and #EHRA of <a href="/escardio/">European Society of Cardiology</a> 

🥉ARNI across EF and
Alfonso Valle (@vallealfonso) 's Twitter Profile Photo

✅The Cardioprotective and Anticancer Effects of SGLT2i 👉 Observational studies suggest SGLT2I protect from cardiotoxic chemotherapy. 👉Preclinical studies show cardioprotective and anticancer effects of SGLT2i. 👉Randomized clinical trials are warranted to test SGLT2I in

✅The Cardioprotective and Anticancer Effects of SGLT2i 

👉 Observational studies suggest SGLT2I protect from cardiotoxic chemotherapy.

👉Preclinical studies show cardioprotective and anticancer effects of SGLT2i.

👉Randomized clinical trials are warranted to test SGLT2I in
FAC (@comunidadfac) 's Twitter Profile Photo

[REVISTA] Ya está disponible la Revista de FAC Vol. 53 Nro. 1 ➕Publicada aquí: revistafac.org.ar/ojs/index.php/… #Revista #FAC

[REVISTA] 
Ya está disponible la Revista de FAC Vol. 53 Nro. 1 

➕Publicada aquí: revistafac.org.ar/ojs/index.php/…

#Revista #FAC
Julia Seller (@juliasellerm) 's Twitter Profile Photo

Top3 heart failure trials in June 2024 🥇Treatment and prevention of HF in patients post–MI JACC Journals 🥈Therapy duration and improvement of LVEF in de novo HF European Society of Cardiology Journals 🥉Semaglutide and NT-proBNP in Obesity-Related HFpEF ➡️ STEP-HFpEF Program JACC Journals

Top3 heart failure trials in June 2024

🥇Treatment and prevention of HF in patients post–MI <a href="/JACCJournals/">JACC Journals</a> 

🥈Therapy duration and improvement of LVEF in de novo HF <a href="/ESC_Journals/">European Society of Cardiology Journals</a> 

🥉Semaglutide and NT-proBNP in Obesity-Related HFpEF ➡️ STEP-HFpEF Program <a href="/JACCJournals/">JACC Journals</a>
Julia Seller (@juliasellerm) 's Twitter Profile Photo

Top3 heart failure trials in June 2025 🥇ACC Scientific statement on the management of obesity in HF JACC Journals 🥈Right heart catheterization in HF European Society of Cardiology Journals 🥉AI ➡️ Enabled analysis of thermography to diagnose ADHF JACC Journals

Top3 heart failure trials in June 2025

🥇ACC Scientific statement on the management of obesity in HF
<a href="/JACCJournals/">JACC Journals</a> 

🥈Right heart catheterization in HF <a href="/ESC_Journals/">European Society of Cardiology Journals</a> 

🥉AI ➡️ Enabled analysis of thermography to diagnose ADHF <a href="/JACCJournals/">JACC Journals</a>